Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
46.73
+0.73 (1.59%)
At close: Jul 31, 2026, 4:00 PM EDT
46.70
-0.03 (-0.06%)
After-hours: Jul 31, 2026, 7:56 PM EDT
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiology | 13.25B | 12.27B | 11.19B | 10.01B | 9.50B | 8.90B | 8.35B | 7.80B | ||||||||||||||||
| Cardiology Growth | 39.39% | 37.81% | 34.14% | 28.40% | 29.86% | 27.65% | 24.40% | 20.24% | ||||||||||||||||
| Endoscopy | 3.04B | 2.98B | 2.92B | 2.85B | 2.78B | 2.72B | 2.69B | 2.64B | ||||||||||||||||
| Endoscopy Growth | 9.25% | 9.64% | 8.56% | 7.80% | 7.18% | 6.67% | 8.22% | 9.68% | ||||||||||||||||
| Urology | 2.73B | 2.72B | 2.71B | 2.62B | 2.47B | 2.32B | 2.20B | 2.10B | ||||||||||||||||
| Urology Growth | 10.48% | 17.33% | 23.14% | 24.99% | 20.65% | 15.54% | 12.02% | 9.56% | ||||||||||||||||
| Neuromodulation | 1.28B | 1.25B | 1.20B | 1.17B | 1.14B | 1.12B | 1.11B | 1.08B | ||||||||||||||||
| Neuromodulation Growth | 12.53% | 11.25% | 8.51% | 8.47% | 10.14% | 12.22% | 13.22% | 12.45% | ||||||||||||||||
| Peripheral Interventions | 702.00M | 1.40B | 2.06B | 2.70B | 2.60B | 2.49B | 2.41B | 2.30B | ||||||||||||||||
| Peripheral Interventions Growth | -73.01% | -43.84% | -14.69% | 17.54% | 16.43% | 14.41% | 14.27% | 11.99% |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 13.39B | 13.19B | 12.86B | 12.37B | 11.67B | 10.91B | 10.21B | 9.53B | ||||||||||||||||
| United States Growth | 14.74% | 20.86% | 25.99% | 29.81% | 29.15% | 25.71% | 21.19% | 16.25% | ||||||||||||||||
| EMEA | 3.59B | 3.54B | 3.45B | 3.35B | 3.33B | 3.27B | 3.23B | 3.15B | ||||||||||||||||
| EMEA Growth | 7.94% | 8.13% | 6.91% | 6.36% | 9.26% | 11.03% | 13.06% | 13.90% | ||||||||||||||||
| APAC | 3.27B | 3.18B | 3.08B | 2.98B | 2.86B | 2.74B | 2.69B | 2.62B | ||||||||||||||||
| APAC Growth | 14.38% | 16.17% | 14.71% | 13.76% | 12.38% | 9.56% | 11.83% | 12.75% | ||||||||||||||||
| LACA | 745.00M | 708.00M | 678.00M | 654.00M | 638.00M | 631.00M | 625.00M | 618.00M | ||||||||||||||||
| LACA Growth | 16.77% | 12.20% | 8.48% | 5.83% | 5.45% | 8.23% | 11.61% | 15.73% |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative | 7.16B | 7.07B | 6.89B | 6.67B | 6.49B | 6.22B | 5.98B | 5.75B | ||||||||||||||||
| Selling, General, and Administrative Growth | 10.34% | 13.74% | 15.09% | 15.91% | 19.44% | 16.45% | 15.30% | 15.62% | ||||||||||||||||
| Research and Development | 2.15B | 2.13B | 2.05B | 1.94B | 1.84B | 1.69B | 1.62B | 1.52B | ||||||||||||||||
| Research and Development Growth | 17.27% | 25.52% | 26.98% | 27.91% | 25.07% | 17.24% | 14.20% | 9.91% | ||||||||||||||||
| Amortization | 918.00M | 910.00M | 897.00M | 894.00M | 874.00M | 862.00M | 857.00M | 840.00M | ||||||||||||||||
| Amortization Growth | 5.03% | 5.57% | 4.67% | 6.43% | 3.68% | 2.62% | 3.38% | 2.44% | ||||||||||||||||
| Litigation-related Net Charges | 270.00M | 194.00M | 194.00M | - | - | - | - | - | ||||||||||||||||
| Royalty Expense | 42.00M | 44.00M | 46.00M | 50.00M | 43.00M | 38.00M | 34.00M | 36.00M | ||||||||||||||||
| Royalty Expense Growth | -2.33% | 15.79% | 35.29% | 38.89% | 2.38% | -15.56% | -26.09% | -23.40% | ||||||||||||||||
| Restructuring Net Charges | 19.00M | 94.00M | 101.00M | 89.00M | 105.00M | 23.00M | 16.00M | 31.00M | ||||||||||||||||
| Restructuring Net Charges Growth | -81.90% | 308.70% | 531.25% | 187.10% | 176.32% | -56.60% | -77.14% | -45.61% | ||||||||||||||||
| Asset and Goodwill Impairment | - | 46.00M | 46.00M | 157.00M | 157.00M | 387.00M | 387.00M | 276.00M | ||||||||||||||||
| Asset and Goodwill Impairment Growth | - | -88.11% | -88.11% | -43.12% | -43.32% | 567.24% | 567.24% | 375.86% | ||||||||||||||||
| Contingent Consideration Net Expense | -28.00M | -17.00M | 18.00M | 10.00M | -24.00M | -17.00M | -5.00M | 10.00M |